Neuropilin-1

Neuropilin-1 Overview

English NameNeuropilin-1Approved Drugs0
Drugs in Clinical Trials1Target SynonymBDCA4,NP1,Neuropilin-1,NRP1,CD304,VEGF165R,Neuropilin 1,Vascular Endothelial Cell Growth Factor 165 Receptor,NRP,Transmembrane Receptor,CD304 Antigen
Highest Development StagePhase 2 Clinical
English NameNeuropilin-1
Target SynonymBDCA4,NP1,Neuropilin-1,NRP1,CD304,VEGF165R,Neuropilin 1,Vascular Endothelial Cell Growth Factor 165 Receptor,NRP,Transmembrane Receptor,CD304 Antigen
Approved Drugs0
Drugs in Clinical Trials1
Highest Development StagePhase 2 Clinical

Neuropilin-1 Product List

  • Product Category

    Protein (5)

  • Product Status

    Launched (5)

  • Species

    Human (3)Mouse (2)

  • Tag

    His Tag (2)Fc Tag (1)His Tag & Avi Tag (1)Mouse IgG Fc Tag (1)

  • Conjugate

    Unconjugated (4)Biotin-labeled (1)

Neuropilin-1 Background

Neuropilin-1 (NRP1) is also known as Vascular endothelial cell growth factor 165 receptor (VEGF165R), CD antigen CD304, which belongs to the neuropilin family. The membrane-bound isoform 1 is a receptor involved in the development of the cardiovascular system, in angiogenesis, in the formation of certain neuronal circuits and in organogenesis outside the nervous system. It mediates the chemorepulsant activity of semaphorins. It binds to semaphorin 3A, The PLGF-2 isoform of PGF, The VEGF-165 isoform of VEGF and VEGF-B. Coexpression with KDR results in increased VEGF-165 binding to KDR as well as increased chemotaxis. It may regulate VEGF-induced angiogenesis. The soluble isoform 2 binds VEGF-165 and appears to inhibit its binding to cells.

Neuropilin-1 Synonyms

NRP1,Neuropilin-1,NRP,VEGF165R,CD304

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
CertepetideCEND-1; iRGD; CIND-1; LSTA1; QLC12102; LSTA-1Phase 2 ClinicalDrugcendr IncAppendiceal Neoplasms; Bile Duct Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Pancreatic Ductal; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Gallbladder Neoplasms; Neoplasm Metastasis; Pancreatic Neoplasms; Triple Negative Breast Neoplasms
Details
  • Overview
  • Product List
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland